Product nameAnti-CD24 antibody [EPR3006(N)]
See all CD24 primary antibodies
DescriptionRabbit monoclonal [EPR3006(N)] to CD24
Tested applicationsSuitable for: WB, IPmore details
Unsuitable for: Flow Cyt,ICC/IF or IHC-P
Species reactivityReacts with: Human
Does not react with: Mouse, Rat
This information is considered to be commercially sensitive.
- Human fetal brain, SH-SY5Y cell and human oligodendroglioma lysates.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferpH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 9% PBS, 40% Glycerol, 0.05% BSA, 50% Tissue culture supernatant
Concentration information loading...
PurityTissue culture supernatant
Our Abpromise guarantee covers the use of ab179821 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000 - 1/10000. Predicted molecular weight: 8 kDa.|
|IP||1/10 - 1/100.|
FunctionModulates B-cell activation responses. Signaling could be triggered by the binding of a lectin-like ligand to the CD24 carbohydrates, and transduced by the release of second messengers derived from the GPI-anchor. Promotes AG-dependent proliferation of B-cells, and prevents their terminal differentiation into antibody-forming cells.
Tissue specificityB-cells. Expressed in a number of B-cell lines including P32/SH and Namalwa. Expressed in erythroleukemia cell and small cell lung carcinoma cell lines. Also expressed on the surface of T-cells.
Involvement in diseaseGenetic variations in CD24 are associated with susceptibility to multiple sclerosis (MS) [MIM:126200]. A multifactorial, inflammatory, demyelinating disease of the central nervous system. Sclerotic lesions are characterized by perivascular infiltration of monocytes and lymphocytes and appear as indurated areas in pathologic specimens (sclerosis in plaques). The pathological mechanism is regarded as an autoimmune attack of the myelin sheat, mediated by both cellular and humoral immunity. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia and bladder dysfunction. Genetic and environmental factors influence susceptibility to the disease. Note=Polymorphisms in CD24 may act as a genetic modifier for susceptibility and progression of MS in some populations, perhaps by affecting the efficiency of CD24 expression on the cell surface.
Sequence similaritiesBelongs to the CD24 family.
Cellular localizationCell membrane.
- Information by UniProt
- CD 24 antibody
- CD24 antibody
- CD24 antigen (small cell lung carcinoma cluster 4 antigen) antibody
All lanes : Anti-CD24 antibody [EPR3006(N)] (ab179821) at 1/1000 dilution
Lane 1 : fetal brain lysate
Lane 2 : SH-SY5Y cell lysate
Lane 3 : human oligodendroglioma lysate
Lysates/proteins at 10 µg per lane.
Predicted band size: 8 kDa
Western blot analysis on immunoprecipitation pellet from (1) SH-SY5Y cell lysate or (2) 1X PBS (negative control) labeling CD24 using ab179821 at 1/10 dilution, and HRP-conjugated anti-rabbit IgG preferentially detecting the non-reduced form of rabbit IgG.
This product has been referenced in:
- Zhang J et al. LGR5, a novel functional glioma stem cell marker, promotes EMT by activating the Wnt/ß-catenin pathway and predicts poor survival of glioma patients. J Exp Clin Cancer Res 37:225 (2018). Read more (PubMed: 30208924) »